Search Results - "Hutti, Jessica E."

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease by Nichols, R Jeremy, Dzamko, Nicolas, Hutti, Jessica E, Cantley, Lewis C, Deak, Maria, Moran, Jennifer, Bamborough, Paul, Reith, Alastair D, Alessi, Dario R

“…The LRRK2 (leucine-rich repeat protein kinase-2) is mutated in a significant number of Parkinson's disease patients, but little is known about its regulation…”
Get more information

p85α SH2 Domain Phosphorylation by IKK Promotes Feedback Inhibition of PI3K and Akt in Response to Cellular Starvation by Comb, William C., Hutti, Jessica E., Cogswell, Patricia, Cantley, Lewis C., Baldwin, Albert S.

“…The IκB kinase (IKK) pathway is an essential mediator of inflammatory, oncogenic, and cell stress pathways. Recently IKK was shown to be essential for…”
Get full text

Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315 by Jakob, Clarissa G, Upadhyay, Anup K, Donner, Pamela L, Nicholl, Emily, Addo, Sadiya N, Qiu, Wei, Ling, Christopher, Gopalakrishnan, Sujatha M, Torrent, Maricel, Cepa, Steven P, Shanley, Jason, Shoemaker, Alexander R, Sun, Chaohong C, Vasudevan, Anil, Woller, Kevin R, Shotwell, J. Brad, Shaw, Bailin, Bian, Zhiguo, Hutti, Jessica E

“…IDH1 plays a critical role in a number of metabolic processes and serves as a key source of cytosolic NADPH under conditions of cellular stress. However, few…”
Get full text

Coordinated Regulation of Toll-Like Receptor and NOD2 Signaling by K63-Linked Polyubiquitin Chains by Abbott, Derek W., Yang, Yibin, Hutti, Jessica E., Madhavarapu, Swetha, Kelliher, Michelle A., Cantley, Lewis C.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

A rapid method for determining protein kinase phosphorylation specificity by Turk, Benjamin E, Hutti, Jessica E, Jarrell, Emily T, Chang, James D, Abbott, Derek W, Storz, Peter, Toker, Alex, Cantley, Lewis C

“…Selection of target substrates by protein kinases is strongly influenced by the amino acid sequence surrounding the phosphoacceptor site. Identification of the…”
Get full text

Development of a high-throughput assay for identifying inhibitors of TBK1 and IKKε by Hutti, Jessica E, Porter, Melissa A, Cheely, Adam W, Cantley, Lewis C, Wang, Xiaodong, Kireev, Dmitri, Baldwin, Albert S, Janzen, William P

“…IKKε and TBK1 are noncanonical IKK family members which regulate inflammatory signaling pathways and also play important roles in oncogenesis. However, few…”
Get full text

IκB Kinase α Phosphorylation of TRAF4 Downregulates Innate Immune Signaling by Marinis, Jill M., Hutti, Jessica E., Homer, Craig R., Cobb, Brian A., Cantley, Lewis C., McDonald, Christine, Abbott, Derek W.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Development of an intracellularly acting inhibitory peptide selective for PKN by Shiga, Kazuhiro, Takayama, Kentaro, Futaki, Shiroh, Hutti, Jessica E, Cantley, Lewis C, Ueki, Katsuko, Ono, Yoshitaka, Mukai, Hideyuki

“…PKNs form a subfamily of the AGC serine/threonine protein kinases, and have a catalytic domain homologous with that of PKC (protein kinase C) in the C-terminal…”
Get more information

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors by Piha-Paul, Sarina A, Sachdev, Jasgit C, Barve, Minal, LoRusso, Patricia, Szmulewitz, Russell, Patel, Sapna Pradyuman, Lara, Jr, Primo N, Chen, Xiaotian, Hu, Beibei, Freise, Kevin J, Modi, Dimple, Sood, Anjla, Hutti, Jessica E, Wolff, Johannes, O'Neil, Bert H

“…Bromodomain and extraterminal (BET) proteins play important roles in transcriptional regulation relevant to cancer pathogenesis, and therapeutic…”
Get full text

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy by Harrison, Claire N, Garcia, Jacqueline S, Somervaille, Tim C P, Foran, James M, Verstovsek, Srdan, Jamieson, Catriona, Mesa, Ruben, Ritchie, Ellen K, Tantravahi, Srinivas K, Vachhani, Pankit, O'Connell, Casey L, Komrokji, Rami S, Harb, Jason, Hutti, Jessica E, Holes, Leanne, Masud, Abdullah A, Nuthalapati, Silpa, Potluri, Jalaja, Pemmaraju, Naveen

“…Targeting the BCL-X pathway has demonstrated the ability to overcome Janus kinase inhibitor resistance in preclinical models. This phase II trial investigated…”
Get full text

Cytosolic DNA Promotes Signal Transducer and Activator of Transcription 3 (STAT3) Phosphorylation by TANK-binding Kinase 1 (TBK1) to Restrain STAT3 Activity by Hsia, Hung-Ching, Hutti, Jessica E., Baldwin, Albert S.

“…Cytosolic DNA can elicit beneficial as well as undesirable immune responses. For example, viral or microbial DNA triggers cell-intrinsic immune responses to…”
Get full text

Building a Human Kinase Gene Repository: Bioinformatics, Molecular Cloning, and Functional Validation by Park, Jaehong, Hu, Yanhui, Murthy, T. V. S., Vannberg, Fredrik, Shen, Binghua, Rolfs, Andreas, Hutti, Jessica E., Cantley, Lewis C., LaBaer, Joshua, Harlow, Ed, Brizuela, Leonardo

“…Kinases catalyze the phosphorylation of proteins, lipids, sugars, nucleosides, and other important cellular metabolites and play key regulatory roles in all…”
Get full text

Oncogenic PI3K Mutations Lead to NF-κB―Dependent Cytokine Expression following Growth Factor Deprivation by HUTTI, Jessica E, PFEFFERLE, Adam D, RUSSELL, Sean C, SIRCAR, Mayukh, PEROU, Charles M, BALDWIN, Albert S

“…The phosphoinositide 3-kinase (PI3K) pathway is one of the most commonly misregulated signaling pathways in human cancers, but its impact on the tumor…”
Get full text

IκB Kinase β Phosphorylates the K63 Deubiquitinase A20 To Cause Feedback Inhibition of the NF-κB Pathway by Hutti, Jessica E., Turk, Benjamin E., Asara, John M., Ma, Averil, Cantley, Lewis C., Abbott, Derek W.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Determining protein kinase substrate specificity by parallel solution-phase assay of large numbers of peptide substrates by Turk, Benjamin E, Hutti, Jessica E, Cantley, Lewis C

“…We describe here a protocol for determining the activity of protein kinases on a large set of peptide substrates. Biotin-tagged peptides are arrayed in…”
Get full text

Evolution of Ime2 Phosphorylation Sites on Cdk1 Substrates Provides a Mechanism to Limit the Effects of the Phosphatase Cdc14 in Meiosis by Holt, Liam J., Hutti, Jessica E., Cantley, Lewis C., Morgan, David O.

“…Progression through meiosis in yeast is governed by the cyclin-dependent kinase Cdk1, in concert with a related kinase called Ime2. It remains unclear how…”
Get full text

VHL Synthetic Lethality Signatures Uncovered by Genotype-Specific CRISPR-Cas9 Screens by Sun, Ning, Petiwala, Sakina, Lu, Charles, Hutti, Jessica E, Hu, Min, Hu, Mufeng, Domanus, Marc H, Mitra, Diya, Addo, Sadiya N, Miller, Christopher P, Chung, Namjin

“…Genome-wide CRISPR-Cas9 essentiality screening represents a powerful approach to identify genetic vulnerabilities in cancer cells. Here, we applied this…”
Get more information

Phosphorylation of the Tumor Suppressor CYLD by the Breast Cancer Oncogene IKKɛ Promotes Cell Transformation by Hutti, Jessica E., Shen, Rhine R., Abbott, Derek W., Zhou, Alicia Y., Sprott, Kam M., Asara, John M., Hahn, William C., Cantley, Lewis C.

“…The noncanonical IKK family member IKKɛ is essential for regulating antiviral signaling pathways and is a recently discovered breast cancer oncoprotein…”
Get full text

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study Evaluating Navitoclax in Combination with Ruxolitinib in Patients with Myelofibrosis (TRANSFORM-1) by Potluri, Jalaja, Harb, Jason, Masud, Abdullah A., Hutti, Jessica E.

“…Background: Myelofibrosis (MF) is a rare myeloproliferative neoplasm with poor clinical outcomes. It is characterized by bone marrow fibrosis and an array of…”
Get full text

A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) by Dilley, Kimberley, Harb, Jason, Jalaluddin, Muhammad, Hutti, Jessica E., Potluri, Jalaja

“…Background: Myelofibrosis (MF) is a rare myeloproliferative neoplasm with limited treatment options and a poor prognosis. Although allogeneic hematopoietic…”
Get full text